In chemotherapy-resistant prostate cancer, MALAT1 was shown to directly interact with EZH2 protein, suggesting that MALAT1 may play a key role as an RNA cofactor of EZH2 and that the EZH2-MALAT1 association may be a new therapeutic target [21]. This evidence concerns the gene EZH2 and prostate carcinoma.